Aug. 18 at 1:35 PM
$KLTO looks well-positioned after a string of recent milestones, including FDA Orphan Drug designation for its lead candidate KLO-202 in ALS, a manufacturing agreement with AvarGene with production already initiated, and the launch of a new research center in Okinawa alongside expanded internal R&D capabilities. The company also strengthened its balance sheet with
$11.7M in financing, completed its Nasdaq uplisting, and retained global rights through its SkyRei agreement. With these steps, KLTO is building momentum toward IND-enabling studies and clinical advancement in large markets like ALS, Alzheimer’s, and Parkinson’s, putting it in a stronger position to capture value in the
$8B+ neurodegenerative disease space.
LFG!
